Clinicaltrialsofrivaroxabanin patients with atrial fibrillation incontextofevidence-basedmedicine

Download in PDF

Efficacy of rivaroxaban in the prevention of ischemic stroke and systemic emboli in patients with atrial fibrillation was established the 3 phase randomized clinical trial (ROCKET AF). Real-life evidence for stroke prevention by rivaroxaban includes both retrospective studies (PMSS, REVISIT-US, RELIEF) and international prospective observational study (XANTUS). In these studies, the efficacy and safety of rivaroxaban were comparable to those in the randomized clinical trial.

Key words

Atrial fibrillation, novel oral anticoagulants, observational studies.